Last reviewed · How we verify

NCT03451877

TGFB1 And LAMA1 Gene Polymorphisms in High Myopia

Completed NA Last updated 5 March 2018
What this trial tests

NA trial testing TGFB1 AND LAMA1 GENE POLYMORPHISMS in High Myopia in 151 participants. Completed in 1 June 2017.

Timeline
1 December 2012
Primary endpoint
1 December 2016
1 June 2017

Quick facts

Lead sponsorEge University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposescreening
Enrollment151
Start date1 December 2012
Primary completion1 December 2016
Estimated completion1 June 2017

Drugs / interventions tested

Conditions studied

Sponsor

Ege University

Who can join

Adults 3 to 13, any sex, with High Myopia or Gene Mutations. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aimed to investigate TGFB1 and LAMA1 gene polymorphisms in children with high myopia in order to determine the genetic basis of large myopic shifts causing severe visual impairment and complications. Seventy-four children with high myopia (≥6 diopters \[D\]; study group) and 77 emmetropic children (±0.5D; control group) were included. Genetic and polymorphism analyses were performed in the Medical Genetics Laboratory using DNA purified from the patients' blood samples.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for High Myopia

Currently open trials in the same condition.

Other Ege University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03451877.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing